Prodrugs for improved aqueous solubility

Water-Insoluble Drug Formulation, Second Edition

Volumn , Issue , 2008, Pages 437-466

  Neau, Steven H ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123271827     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (175)

1. Albert, A. 1958. Chemical aspects of selective toxicity. Nature 182:421-423.
2. Albert, A. 1964. Selective Toxicity, 57-63. New York: John Wiley & Sons, Inc.
3. Alexander, J., R. Cargill, S. R. Michelson, and H. Schwam. 1988. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J. Med. Chem. 31:318-322.
4. Al-Ghananeem, A. M., A. A. Traboulsi, L. W. Dittert, and A. A. Hussain. 2002. Targeted brain delivery of 17B-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech 3:E5.
5. Altomare, C., G. Trapani, A. Latrofa, M. Serra, G. Biggio, and G. Liso. 2003. Highly water-soluble derivatives of the anesthetic agent propofol: in vitro and in vivo evaluation of cyclic amino acid esters. Eur. J. Pharm. Sci. 20:17-26.
6. Ambrose, P. J. 1984. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin. Pharmacokin. 9:222-238.
7. Amidon, G. L. 1981. Drug derivatization as a means of solubilization: physicochemical and biochemical strategies. In Techniques of Solubilization of Drugs, edited by S. H. Yalkowsky, 183-211. New York: Marcel Dekker, Inc.
8. Amidon, G. L., R. S. Pearlman, and G. D. Leesman. 1977. Design of prodrugs through consideration of enzyme-substrate specificities. In Design of Biopharmaceutical Properties through Prodrugs and Analogs, edited by E. B. Roche, 281-315. Washington, D.C.: American Pharmaceutical Association.
9. Amidon, G. L., G. D. Leesman, and R. L. Elliott. 1980. Improving intestinal absorption of water-insoluble compounds: a membrane metabolism strategy. J. Pharm. Sci. 69:1363-1368.
10. Anderson, B. D. 1980. Thermodynamic considerations in physical property improvement through prodrugs. In Physical Chemical Properties of Drugs, edited by S. H. Yalkowsky, A. A. Sinkula, and S. C. Valvani, 231-266. New York: Marcel Dekker, Inc.
11. Anderson, B. D. 1985. Prodrugs for improved formulation properties. In Design of Prodrugs, edited by H. Bundgaard, 243-269. New York: Elsevier Science Publishers.
12. Anderson, B. D. and R. A. Conradi. 1980. Prostaglandin prodrugs. VI. Structure-thermodynamic activity and structure-aqueous solubility relationships. J. Pharm. Sci. 69:424-430.
13. Anderson, B. D. and R. A. Conradi. 1987. Application of physical organic concepts to in vitro and in vivo lability design of water soluble prodrugs. In Bioreversible Carriers in Drug Design: Theory and Application, edited by E. B. Roche, 121-163. New York: Pergamon Press.
14. Anderson, B. D. and V. Taphouse. 1981. Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate. J. Pharm. Sci. 70:181-186.
15. Anderson, B. D., R. A. Conradi, and K. Johnson. 1983. Influence of premicellar and micellar association on the reactivity of methylprednisolone 21-hemiesters in aqueous solution. J. Pharm. Sci. 72:448-154.
16. Anderson, B. D., R. A. Conradi, and W. J. Lambert. 1984. Carboxyl group catalysis of acyl transfer reactions in corticosteroid 17- and 21-monoesters. J. Pharm. Sci. 73:604-611.
17. Anderson, B. D., R. A. Conradi, and K. E. Knuth. 1985. Strategies in the design of solution-stable, water-soluble prodrugs. I. A physical-organic approach to pro-moiety selection for 21-esters of corticosteroids. J. Pharm. Sci. 74:365-374.
18. Ariens, E. J. 1966. Molecular pharmacology, a basis for drug design. Progr. Drug Res. 10:429-529.
19. Banerjee, P. K. and G. L. Amidon. 1985. Design of prodrugs based on enzyme-substrate specificity. In Design of Prodrugs, edited by H. Bundgaard, 93-134. New York: Elsevier Science Publishers.
20. Bansai, P. C., I. H. Pitman, J. N. S. Tam, M. Mertes, and J. J. Kaminski. 1981a. N-Hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs. I. N-Hydroxymethylation of uracils. J. Pharm. Sci. 70:850-854.
21. Bansai, P. C., I. H. Pitman, and T. Higuchi. 1981b. N-Hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs. II. Possible prodrugs of allopurinol, glutethimide, and phenobarbital. J. Pharm. Sci. 70:855-857.
22. Baurain, R., M. Masquelier, D. Deprez-De Campeneere, and A. Trouet. 1980. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemia cells in vitro and in vivo. J. Med. Chem. 23:1171-1174.
23. Bodor, N. 1981. Novel approaches in prodrug design. Drugs Future 6:165-182.
24. Bodor, N. 1982. Novel approaches in prodrug design. In Optimization of Drug Delivery, edited by H. Bundgaard, A. B. Hansen, and H. Kofod, 156-174. Copenhagen: Munksgaard.
25. Brown, J. P., G. V. McGarraugh, T. M. Parkinson, R. E. Wingard, and A. B. Onderdonk. 1983. A polymeric drug for treatment of inflammatory bowel disease. J. Med. Chem. 26:1300-1307.
26. Bundgaard, H. 1982. Novel bioreversible derivatives of amides, imides, ureides, amines and other chemical entities not readily derivatizable. In Optimization of Drug Delivery, edited by H. Bundgaard, A. B. Hansen, and H. Kofod, 178-197. Copenhagen: Munksgaard.
27. Bundgaard, H. 1985a. Design of prodrugs: bioreversible derivatives for various functional groups and chemical entities. In Design of Prodrugs, edited by H. Bundgaard, 1-92. New York: Elsevier Science Publishers.
28. Bundgaard, H. 1985b. Formation of prodrugs of amines, amides, ureides, and imides. In Methods in Enzymology, Vol. 112, Part A, edited by K. J. Widder and R. Gree, 347-359. New York: Academic Press, Inc.
29. Bundgaard, H. 1986. Design of prodrugs: bioreversible derivatives for various function groups and chemical entities. In Design of Prodrugs, edited by H. Bundgaard, 1-92. Amstedam: Elsevier Biomedical Press.
30. Bundgaard, H. 1987. Design of bioreversible drug derivatives and the utility of the double prodrug concept. In Bioreversible Carriers in Drug Design: Theory and Application, edited by E. B. Roche, 13-94. New York: Pergamon Press.
31. Bundgaard, H. and E. Falch. 1985a. Allopurinol prodrugs. II. Synthesis, hydrolysis kinetics and physicochemical properties of various N-acyloxymethyl allopurinol derivatives. Int. J. Pharm. 24:307-325.
32. Bundgaard, H. and E. Falch. 1985b. Allopurinol prodrugs. III. Water-soluble N-acyloxymethyl allopurinol derivatives for rectal or parenteral use. Int. J. Pharm. 25:27-39.
33. Bundgaard, H. and M. Johansen. 1982. Kinetics of hydrolysis of plafibride (An ureide N-Mannich base with platelet antiaggregant activity) in aqueous solution and in plasma. Arch. Pharm. Chem., Sci. Ed. 10:139-145.
34. Bundgaard, H. and M. Johansen. 1984. Hydrolysis of N-(A-hydroxyalkyl)benzamide and other N-(A-hydroxyalkyl)amide derivatives: implications for the design of N-acyloxyalkyl-type prodrugs. Int. J. Pharm. 22:45-56.
35. Bundgaard, H. and N. M. Nielsen. 1987. Esters of N, N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents. J. Med. Chem. 30:451-454.
36. Bundgaard, H. and N. M. Nielsen. 1988. Glycolamide esters as a novel biolabile prodrug type for non-steroidal anti-inflammatory carboxylic acid drugs. Int. J. Pharm. 43:101-110.
37. Bundgaard, H., M. Johansen, V. Stella, and M. Cortese. 1982. Pro-drugs as drug delivery systems. XXI. Preparation, physicochemical properties and bioavailability of a novel water-soluble pro-drug type for carbamazepine. Int. J. Pharm. 10:181-192.
38. Bundgaard, H., C. Larsen, and E. Arnold. 1984a. Prodrugs as drug delivery systems. XXVII. Chemical stability and bioavailability of a water-soluble prodrug of metronidazole for parenteral administration. Int. J. Pharm. 18:79-87.
39. Bundgaard, H., C. Larsen, and P. Thorbek. 1984b. Prodrugs as drug delivery systems. XXVI. Preparation and enzymatic hydrolysis of various water-soluble amino acid esters of metronidazole. Int. J. Pharm. 18:67-77.
40. Bundgaard, H., E. Falch, and E. Jensen. 1989. A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or an NH-acidic group. J. Med. Chem. 32:2503-2507.
41. Bundgaard, H., E. Jensen, E. Falch, and S. B. Pedersen. 1990. Allopurinol prodrugs. V. Water-soluble N-substituted(aminomethyl)benzoyloxymethylallopurinolderivatives forparenteralorrectaldelivery. Int. J. Pharm. 64:75-87.
42. Bundgaard, H., E. Jensen, and E. Falch. 1991. Water-soluble, solution-stable, and biolabile N-substituted (aminomethyl)benzoate ester prodrugs of acyclovir. Pharm. Res. 8:1087-1093.
43. Burke, J. T., W. A. Wargin, R. J. Sherertz, K. L. Sanders, M. R. Blum, and F. A. Sarubbi. 1982. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function. J. Pharmacokin. Biopharm. 10:601-614.
44. Buur, A. and H. Bundgaard. 1984a. Prodrugs of 5-fluorouracil. I. Hydrolysis kinetics and physicochemical properties of various N-acyl derivatives of 5-fluorouracil. Int. J. Pharm. 21:349-364.
45. Buur, A. and H. Bundgaard. 1984b. Prodrugs of 5-fluorouracil. II. Hydrolysis kinetics, bioactivation, solubility and lipophilicity of N-alkoxycarbonyl derivatives of 5-fluorouracil. Arch. Pharm. Chem., Sci. Ed. 12:37-44.
46. Caprariis, P. D., F. Palagiano, F. Bonina, L. Montenegro, M. D'Amico, and F. Rossi. 1994. Synthesis and pharmacological evaluation of oligoethylene ester derivatives as indomethacin oral prodrugs. J. Pharm. Sci. 83:1578-1581.
47. Cecchi, R., L. Rusconi, M. C. Tanzi, F. Danusso, and P. J. Ferruti. 1981. Synthesis and pharmacological evaluation of poly(oxyethylene) derivatives of 4-isobutylphenyl-2-propionic acid (ibuprofen). J. Med. Chem. 24:622-625.
48. Charton, M. 1977. The prediction of chemical lability through substituent effects. In Design of Biopharmaceutical Properties through Prodrugs and Analogs, edited by E. B. Roche, 228-280. Washington, D.C.: American Pharmaceutical Association.
49. Charton, M. 1985. Prodrug lability prediction through the use of substituent effects. In Methods in Enzymology, Vol. 112, Part A, edited by K. J. Widder and R. Gree, 323-340. New York: Academic Press, Inc.
50. Cho, M. J., V. H. Sethy, and L. C. Haynes. 1986. Sequentially labile water-soluble prodrugs of alprazolam. J. Med. Chem. 29:1346-1350.
51. Chung, Y. and H. Cho. 2004. Preparation of highly water soluble tacrolimus derivatives: poly(ethylene glycol) esters as potential prodrugs. Arch. Pharm. Res. 27:878-883.
52. Colaizzi, J. L. and W. H. Pitlick. 1982. Oral drug-delivery systems for prescription pharmacy. In Pharmaceutics and Pharmacy Practice, edited by G. S. Banker and R. K. Chalmers, 184-237. Philadelphia, PA: J. B. Lippincott Company.
53. Colla, L., E. De Clercq, R. Busson, and H. Vanderhaeghe. 1983. Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyehtoxy)methyl]guanine]. J. Med. Chem. 26:602-604.
54. Culty, M., H. A. Nguyen, and C. B. Underhill. 1992. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J. Cell Biol. 116:1055-1062.
55. Dal Pozzo, A. and M. Acquasaliente. 1983. New highly water-soluble phenytoin prodrugs. Int. J. Pharm. 81:263-265.
56. Damen, E. W. P., L. Braamer, and H. W. Scheeren. 1998. Lanthanide trifluoromethanesulfonate catalysed selective acylation of 10-deacetylbaccatin III. Tetrahedron Lett. 39:6081-6082.
57. Damen, E. W. P., P. H. G. Wiegerinck, L. Braamer, D. Sperling, D. de Vos, and H. W. Scheeren. 2000. Paclitaxel esters of malic acid as prodrugs with improved water solubility. Bioorg. Med. Chem. 8:427-432.
58. De Groot, F. M. H., A. Carsten, R. Koekkoek, P. H. Beusker, and H. W. Scheeren. 2003. Cascade-release dendrimers liberate all end groups upon a single triggering event in the dendritic core. Angew. Chem. Int. Ed. 42:4490-4494.
59. Deutsch, M., J. A. Glinski, M. Hernandez, R. D. Haugwitz, V. L. Narayanan, M. Suffness, and L. H. Zalkow. 1989. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 32:788-792.
60. Digenis, G. A. and J. V. Swintowsky. 1975. Drug latentiation. Handbook Exp. Pharmacol. 28:86-112.
61. Djaldetti, R., R. Inzelberg, N. Giladi, A. D. Korczyn, Y. Peretz-Aharon, M. J. Rabey, Y. Herishano, S. Honigman, S. Badarny, and E. Melamed. 2002. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov. Disord. 17:297-302.
62. Doh, M. J., Y. J. Jung, I. Kim, H. S. Kong, and Y. M. Kim. 2003. Synthesis and in vitro properties of prednisolone 21-sulfate sodium as a colon-specific prodrug of prednisolone. Arch. Pharm. Res. 26:258-263.
63. Duncan, R., L. C. Seymour, L. Scarlett, J. B. Lloyd, P. Rejmanova, and J. Kopecek. 1986. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880:62-71.
64. Duncan, R., P. Kopeckova-Rejmanova, J. Strohalm, I. Hume, H. C. Cable, J. Pohl, J. B. Lloyd, and J. Kopecek. 1987. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer 55:165-174.
65. Duncan, R., S. Gac-Breton, R. Keane, R. Musila, Y. N. Sat, R. Satchi, and F. Searle. 2001. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Rel. 74:135-146.
66. Filipovic-Grcic, J., D. Maysinger, B. Zorc, and I. Jalsenjak. 1995. Macromolecular prodrugs. IV. Alginate-chitosan microspheres of PHEA-L-dopa adduct. Int. J. Pharm. 116:39-44.
67. Fleisher, D., B. H. Stewart, and G. L. Amidon. 1985. Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. In Methods in Enzymology, Vol. 112, Part A, edited by K. J. Widder and R. Gree, 360-381. New York: Academic Press, Inc.
68. Flynn, G. L. and D. J. Lamb. 1970. Factors influencing solvolysis of corticosteroid-21-phosphate esters. J. Pharm. Sci. 59:1433-1438.
69. Freed, L. E., G. Vunjak-Novakovic, R. J. Biron, D. B. Eagles, D. C. Lesnoy, S. K. Barlow, and R. Langer. 1994. Biodegradable polymer scaffolds for tissue engineering. Bio/Technology 12:689-693.
70. Garrett, E. R. and M. E. Royer. 1962. Prediction of stability in pharmaceutical preparations XI. J. Pharm. Sci. 51:451-455.
71. Glazko, A. J., W. A. Dill, A. W. Kinkel, J. R. Goulet, W. J. Holloway, and R. A. Buchanan. 1977. Absorption and excretion of parenteral doses of chloramphenicol sodium succinate (CMS) in comparison with peroral doses of chloramphenicol (CM). Clin. Pharmacol. Ther. 21:104.
72. Greenwald, R. B., C. W. Gilbert, A. Pendri, C.D. Conover, J. Xia, A. Martinez. 1996. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs and in vivo effectiveness. J. Med. Chem. 39:424-431.
73. Greenwald, R. B., A. Pendri, C.D. Conover, Y. H. Choe, C. W. Gilbert, A. Martinez, J. Xia, H. Wu, and M. Hsue. 1998. Camptothecin-20-PEG ester transport forms: the effect of spacer group on antitumor activity. Biorg. Med. Chem. 6:551-562.
74. Hare, L. E., K. C. Yeh, C. A. Ditzler, F. G. McMahon, and D. E. Duggan. 1975. Bioavailability of dexamethasone. II. Dexamethasone phosphate. Clin. Pharmacol. Ther. 18:330-337.
75. Harper, N. J. 1959. Drug latentiation. J. Med. Pharm. Chem. 1:467-500.
76. Harper, N. J. 1962. Drug latentiation. Prog. Drug Res. 4:221-294.
77. Heimbach, T., D. M. Oh, L. Y. Li, N. Rodriguez-Hornedo, G. Garcia, and D. Fleisher. 2003. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. Int. J. Pharm. 261:81-92.
78. Hong, W.-H. and D. H. Szulczewski. 1984. Stability of vidarabine-5'-phosphate in aqueous solutions. J. Parent. Sci. Technol. 38:60-64.
79. a values of estrogens. J. Pharm. Sci. 66:624-627.
80. Hutchinson, I., S.A. Jennings, B. R. Vishnuvajjala, A. D. Westwell, and M. F. G. Stevens. 2002. Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J. Med. Chem. 45:744-747.
81. Johansen, M. and H. Bundgaard. 1981a. Decomposition of rolitetracycline and other N-Mannich bases and of N-hydroxymethyl derivatives in the presence of plasma. Arch. Pharm. Chem., Sci. Ed. 9: 40-42.
82. Johansen, M. and H. Bundgaard. 1981b. Pro-drugs as drug delivery systems. XVI. Novel water-soluble pro-drug types for chlorzoxazone by esterification of the N-hydroxymethyl derivative. Arch. Pharm. Chem., Sci. Ed. 9:43-54.
83. Johnson, K., G. L. Amidon, and S. Pogany. 1985. Solution kinetics of a water-soluble hydrocortisone prodrug: hydrocortisone-21-lysinate. J. Pharm. Sci. 74:87-89.
84. Jones, G. 1985. Decreased toxicity and adverse reactions via prodrugs. In Design of Prodrugs, edited by H. Bundgaard, 199-241. New York: Elsevier Science Publishers.
85. Jones, R. J. and N. Bischofberger. 1995. Minireview: nucleotide prodrugs. Antiviral Res. 27:1-17.
86. Jones, L. A., A. R. Moorman, S.D. Chamberlain, P. de Miranda, D. J. Reynolds, C. L. Burns, and T. A. Krenistky. 1992. Di- and triester prodrugs of the Varicella-Zoster antiviral agent 6-methoxypurine arabinoside. J. Med. Chem. 35:56-63.
87. Juntunen, J., J. Vepsalainen, R. Niemi, K. Laine, and T. Jarvinen. 2003. Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether. J. Med. Chem. 46:5083-5086.
88. Kauffman, R. E., J. N. Miceli, L. Strebel, J. A. Buckley, A. K. Done, and A. S. Dajani. 1980. Pharmacokinetics of chloramphenicol (CAP) and chloramphenicol-succinate (CAP-Succ) in infants and children. Clin. Pharmacol. Ther. 27:288-289.
89. Kearney, A. S. and V. J. Stella. 1992. The in vitro enzymatic labilities of chemically distinct phosphomonoesters prodrugs. Pharm. Res. 9:497-503.
90. Kerr, S. G. and T. I. Kalman. 1992. Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2', 3'-dideoxycytidine and its 3'-fluoro derivative. J. Med. Chem. 35:1996-2001.
91. Khmelnitsky, Y. L., C. Budde, J. M. Arnold, A. Usyatinsky, D. S. Clark, and J. S. Dordick. 1997. Synthesis of water-soluble paclitaxel derivatives by enzymatic acylation. J. Am. Chem. Soc. 119:11554-11555.
92. Kopecek, J. 1991. Targetable polymeric anticancer drugs. Temporal control of drug activity. Ann. NY Acad. Sci. 618:335-344.
93. Kopecek, J., P. Kopeckova, T. Minko, and Z. Lu. 2000. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:61-81.
94. Kovach, I. M., I. H. Pittman, and T. Higuchi. 1975. Amino acid esters of phenolic drugs as potentially useful prodrugs. J. Pharm. Sci. 64:1070-1071.
95. Kramer, W. G., E. R. Rensimer, C. D. Ericson, and L. K. Pickering. 1984. Comparative bioavailability of intravenous and oral chloramphenicol in adults. J. Clin. Pharmacol. 24:181-186.
96. Krise, J. P. 1999. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. J. Med. Chem. 42:3094-3100.
97. Krise, J. P., S. Narisawa, and V. J. Stella. 1999a. A novel prodrug approach for tertiary amines. 2. Physico-chemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J. Pharm. Sci. 88:922-927.
98. Krise, J. P., J. Zygmunt, G. I. Georg, and V. J. Stella. 1999b. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. J. Med. Chem. 42:3094-3100.
99. Kwee, K. S. L. and L. M. L. Stolk. 1984. Formulation of a stable vidarabine phosphate injection, Pharm. Weekblad, Sci. Ed. 6:101-104.
100. Lallemand, F., O. Felt-Baeyens, S. Rudaz, A. R. Hamel, F. Hubler, R. Wenger, M. Mutter, K. Besseghir, and R. Gurny. 2005a. Conversion of cyclosporine Aprodrugs in human tears vs. rabbits tears. Eur. J. Pharm. Biopharm. 59:51-56.
101. Lallemand, F., P. Perottet, O. Felt-Baeyens, W. Kloeti, F. Philippoz, J. Marfurt, K. Besseghir, and R. Gurny. 2005b. A water-soluble prodrug of cyclosporine A for ocular application: a stability study, Eur. J. Pharm. Sci. 26:124-129.
102. Laurent, T. C., U. B. G. Laurent, and J. R. E. Fraser. 1995. Functions of hyaluronan. Ann. Rheum. Dis. 54:429-432.
103. Lee, J. S., Y. J. Jung, M. J. Doh, and Y. M. Kim. 2001. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev. Ind. Pharm. 27:331-336.
104. Lee, W. A., H. F.-L. Lu, P. W. Maffuid, M. T. Botet, P. A. Baldwin, T. A. Benkert, and C. K. Klingbeil. 1992. The synthesis, characterization and biological testing of a novel class of mucosal permeation enhancers. J. Control. Rel. 22:223-237.
105. Leppanen, J., J. Huuskonen, J. Savolainen, T. Nevalainen, H. Taipale, J. Vepsalainen, J. Gynther, and T. Jarvinen. 2000. Synthesis of a water-soluble prodrug of entacapone. Bioorg. Med. Chem. Lett. 10:1967-1969.
106. Luo, Y. and G. D. Prestwich. 1999. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjugate Chem. 10:755-763.
107. Maeda, H., L. Seymour, and Y. Miyamoto. 1992. Conjugates of antitumor agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:351-362.
108. Magri, N. F. 1985. Modified taxols as anticancer agents. Ph.D. dissertation, Virginia Polytechnic Institute and State University, Blacksburg, VA.
109. Magri, N. F. and D. G. I. Kingston. 1988. Modified taxols. 4. Synthesis and biological activity of taxols modified in the side chain. J. Nat. Prod. 51:298-306.
110. Martin, B. D., S. A. Ampofo, R. J. Linhardt, and J. S. Dordick. 1992. Biocatalytic synthesis of sugar-containing polyacrylate-based hydrogels. Macromolecules 25:7081-7085.
111. Mathew, A. E., M. R. Mejillano, J. P. Nath, R. H. Himes, and V. J. Stella. 1992. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem. 35:145-151.
112. McLeod, A. D., D. R. Friend, and T. N. Tozier. 1993. Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery. Int. J. Pharm. 92:105-114.
113. Melby, J. C. and R. H. Silber. 1981. Clinical pharmacology of water-soluble corticosteroid esters. Am. Pract. Digest 12:156-161.
114. Melby, J. C. and M. St. Cyr. 1961. Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. Metabolism 10:75-82.
115. Mellado, W. F., N. F. Magri, D. G. I. Kingston, R. Garcia-Arenas, G. A. Orr, and S. B. Horwitz. 1984. Preparation and biological activity of taxol acetates. Biochem. Biophys. Res. Commun. 124:329-336.
116. Merck Index, 10th ed. 1983. edited by M. Windholz, S. Budavari, R. F. Blumetti, and E. S. Otterbein, Rahway, NJ: Merck & Co.
117. Miyabo, S., T. Nakamura, S. Kuwazima, and S. Kishida. 1981. A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man. Eur. J. Clin. Pharmacol. 20:277-282.
118. Mollmann, H., P. Rhodewald, J. Barth, M. Verho, and H. Derendorf. 1989. Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm. Drug Dispos. 10:453-464.
119. Molteni, L. 1982. Effects of the polysaccharidic carrier on the kinetic fate of drugs linked to dextran and inulin in macromolecular compounds. In Optimization of Drug Delivery, edited by H. Bundgaard, A. B. Hansen, and H. Kofod, 285-300. Copenhagen: Munksgaard.
120. Mørk, N., H. Bundgaard, M. Shalmi, and S. Christensen. 1990. Furosemide prodrugs: synthesis, enzymatic hydrolysis and solubility of various furosemide esters. Int. J. Pharm. 60:163-169.
121. Nichifor, M. and E. H. Schacht, Chemical and enzymatic hydrolysis of dipeptide derivatives of 5-fluorouracil. J. Control. Rel. 47:271-281.
122. Nicolaou, K. C., C. Riemer, M. A. Kerr, D. Rideout, and W. Wrasidlo. 1993. Design, synthesis and biological activity of protaxols. Nature 364:464-466.
123. Nielsen, A. B., A. Buur, and C. Larsen. 2005. Bioreversible quaternary N-acyloxymethyl derivatives of the tertiary amines bupivacaine and lidocaine-synthesis, aqueous solubility and stability in buffer, human plasma and simulated intestinal fluid. Eur. J. Pharm. Sci. 24:433-440.
124. Nielsen, L. S., H. Bundgaard, and E. Falch. 1992. Prodrugs of thiabendazole with increased water-solubility. Acta Pharm. Nord. 4:43-49.
125. Nielsen, L. S., F. Sløk, and H. Bundgaard. 1994. N-Alkoxycarbonyl prodrugs of mebendazole with increased water solubility. Int. J. Pharm. 102:231-239.
126. Niethammer, A., G. Gaedicke, H. N. Lode, and W. Wrasidlo. 2001. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjugate Chem. 12:414-420.
127. Notari, R. E. 1973. Pharmacokinetics and molecular modification: implications in drug design and evaluation. J. Pharm. Sci. 62:865-881.
128. Notari, R. E. 1985. Theory and practice of prodrug kinetics, In Methods in Enzymology, Vol. 112, Part A, edited by K. J. Widder and R. Gree, 309-323. New York: Academic Press, Inc.
129. Orlowski, M., H. Mizoguchi, and S. Wilk. 1979. N-Acyl-y-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs. J. Pharmacol. Exp. Ther. 212:167-172.
130. Pitman, I. H. 1976. Three chemical approaches towards the solubilisation of drugs: control of enantiomer composition, salt selection, and pro-drug formation. Austr. J. Pharm. Sci. NS5:17-19.
131. Prestwich, G. D., D. M. Marecak, J. F. Marecek, K. P. Vercruysse, and M. R. Ziebell. 1998. Chemical modification of hyaluronic acid for drug delivery, biomaterials, and biochemical probes. In The Chemistry, Biology, and Medical Applications of Hyaluronan and Its Derivatives, T. C. Laurent, ed., Portland Press, London, 43-65.
132. Prusiner. P. and M. Sundaralingam. 1972. Stereochemistry of nucleic acids and their constituents XXIX. Crystal and molecular structure of allopurinol, a potent inhibitor of xanthine oxidase. Acta Cryst. B28:2148-2152.
133. Radhakrishnan, A. N. 1977. Intestinal dipeptidases and dipeptide transport in the monkey and in man. In Peptide Transport and Hydrolysis, Ciba Foundation Symposium, 37-59. New York: Elsevier Science Publishers.
134. Repta, A. J., B. J. Rawson, R. D. Shaffer, K. B. Sloan, N. Bodor, and T. Higuchi. 1975. Rational development of a soluble prodrug of a cytotoxic nucleoside: preparation and properties of arabinosyladenine 5'-formate. J. Pharm. Sci. 64:392-396.
135. Rihova, B., J. Kopecek, P. Kopeckova-Rejmanova, J. Strohalm, D. Plocova, and H. Semoradova. 1986. Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers. J. Chromatogr. 376:221-233.
136. Rimoli, M. G., L. Avallone, P. de Caprariis, A. Galeone, F. Forni, M. A. Vandelli. 1999. Synthesis and characterization of poly(d, l-lactic acid)-idoxuridine conjugate. J. Control. Rel. 58:61-68.
137. Rodrigues, P. C. A., U. Beyer, P. Schumacher, T. Roth, H. H. Fiebig, C. Unger, L. Messori, P. L. Orioli, D. H. Paper, R. Mulhaupt, and F. Kratz. 1999. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Biorg. Med. Chem. 7: 2517-2524.
138. Roy, S. D. and E. Manoukian. 1994. Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin. J. Pharm. Sci. 83:1548-1553.
139. Sadafi, M., R. Oliyai, and V. J. Stella. 1993. Phosphoryloxymethyl carbamates and carbonates-Novel water-soluble prodrugs for amines and hindered alcohols. Pharm. Res. 10:1350-1355.
140. Schacht, E., L. Ruys, J. Vermeersch, and J. P. Remon. 1984. Polymer-drug combinations: synthesis and characterization of modified polysaccharides containing procainamide moieties. J. Control. Rel. 1:33-46.
141. Scriba, G. K. E. 1993. Phenytoin-lipid conjugates: chemical, plasma esterase-mediated, and pancreatic lipase-mediated hydrolysis in vitro. Pharm. Res. 10:1181-1186.
142. Sezaki, H. 1989. Biopharmaceutical aspects of a chemical approach to drug delivery: macromolecule-drug conjugates. Yakugaku Zasshi 109:611-621.
143. Sezaki, H. and M. Hashida. 1984. Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1:1-38.
144. Simmons, D. M., G. A. Portmann, and V. R. Chandran. 1995. Danazol amino acid prodrugs in vitro and in situ biopharmaceutical evaluation. Drug Dev. Ind. Pharm. 21:687-708.
145. Sinkula, A. A. 1975. Prodrug approach in drug design. In Annual Reports in Medicinal Chemistry, Vol. 10, edited by R. V. Heinzelman, 306-316. New York: Academic Press.
146. Sinkula, A. A. 1977. Perspective on prodrugs and analogs in drug design. In Design of Biopharmaceutical Properties through Prodrugs and Analogs, edited by E.B. Roche, 1-17. Washington, D.C.: American Pharmaceutical Association.
147. Sinkula, A. A. and S. H. Yalkowsky. 1975. Rationale for design of biologically reversible drug derivatives: prodrugs. J. Pharm. Sci. 64:181-210.
148. Sloan, K. B., S. A. M. Koch, and K. G. Siver. 1984. Mannich base derivatives of theophylline and 5-fluorouracil: syntheses, properties and topical delivery characteristics. Int. J. Pharm. 21:251-264.
149. Stella, V. 1975. Pro-drugs: an overview and definition. In Pro-drugs as Novel Drug Delivery Systems, edited by T. Higuchi and V. Stella, 1-115. Washington, D.C.: American Chemical Society.
150. Stella, V. J., S. Martodihardjo, K. Terada, and V. M. Rao. 1998. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications. J. Pharm. Sci. 87:1235-1241.
151. Stinchcomb, A. L., R. Dua, A. Paliwal, R. W. Woodard, and G. L. Flynn. 1995. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res. 12:1526-1529.
152. Strebel, L., J. Miceli, R. Kauffman, R. Poland, A. Dajani, and A. Done. 1980. Pharmacokinetics of chloramphenicol (CAP) and chloramphenicol-succinate (CAP-Succ) in infants and children. Clin. Pharmacol. Ther. 27:288-289.
153. Takata, J., Y. Karube, M. Hanada, K. Matsunaga, Y. Matsushima, T. Sendo, and T. Aoyama. 1995a. Vitamin K prodrugs. 1. Synthesis of amino acid esters of menahydroquinone-4 and enzymatic reconversion to an active form. Pharm. Res. 12:18-23.
154. Takata, J., Y. Karube, Y. Nagata, and Y. Matsushima. 1995b. Water-soluble prodrugs of vitamin E. 1. Preparation and enzymatic hydrolysis of aminoalkanecarboxylic acid esters of d-A-tocopherol. J. Pharm. Sci. 84:96-100.
155. Tammara, V. K., M. M. Narurkar, A. M. Crider, and M. A. Khan. 1994. Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation. J. Pharm. Sci. 83:644-648.
156. Taylor, H. E. and K. B. Sloan. 1998. 1-Alkyloxymethyl prodrugs of 5-fluorouracil (5-FU): synthesis, physicochemical properties, and topical delivery of 5-FU. J. Pharm. Sci. 87:15-20.
157. Therisod, M. and A. M. Klibanov. 1986. Facile enzymatic preparation of monoacylated sugars in pyridine. J. Am. Chem. Soc. 108:5638-5640.
158. Ulbrich, K. and V. Subr. 2004. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. 56:1023-1050.
159. Varia, S. A. and V. J. Stella. 1984a. Phenytoin prodrugs. VI. In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J. Pharm. Sci. 73:1087-1090.
160. Varia, S., S. Schuller, K. B. Sloan, and V. J. Stella. 1984a. Phenytoin prodrugs. III. Water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73:1068-1073.
161. Varia, S. A., S. Schuller, and V. J. Stella. 1984b. Phenytoin prodrugs. IV. Hydrolysis of various 3-(hydroxymethyl)phenytoin esters. J. Pharm. Sci. 73:1074-1080.
162. Vartikovski, L., Z. R. Lu, K. Mitchell, I. de Aos, and J. Kopecek. 2001. Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. J. Control. Rel. 74:275-281.
163. Vej-Hansen, B. and H. Bundgaard. 1979. Kinetics of degradation of rolitetracycline in aqueous solutions and reconstituted formulation. Arch. Pharm. Chem., Sci. Ed. 7:65-77.
164. Vercruysse, K. P. and G. D. Prestwich. 1998. Hyaluronate derivatives in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 15:513-555.
165. Vermeersch, H., J. P. Remon, D. Permentier, and E. Schacht. 1990. In vitro antitrichomonal activity of water-soluble prodrug esters of metronidazole. Int. J. Pharm. 60:253-260.
166. Vyas, D. M., H. Wong, A. R. Crosswell, A. M. Casazza, J. O. Knipe, S. W. Mamber, and T. W. Doyle. 1993. Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg. Med. Chem. Lett. 3:1357-1360.
167. Watanabe, K. A., A. Matsuda, M. J. Halat, D. H. Hollenberg, J. S. Nisselbaum, and J. J. Fox. 1981. Nucleosides. 114. 5'-O-Glucuronides of 5-fluorouridine and 5-fluorocytidine. Masked precursors of anticancer nucleosides. J. Med. Chem. 24:893-897.
168. Weiner, B.-Z. and A. Zilkha. 1973. Polyethylene glycol derivatives of procaine. J. Med. Chem. 16:573-574.
169. Wilk, S., H. Mizoguchi, and M. Orlowski. 1978. γ-Glutamyl dopa: a kidney-specific dopamine precursor. J. Pharmacol. Exp. Ther. 206:227-232.
170. N 2(P) mechanism in the phosphorylation of alkaline phosphatase by substrate. J. Chem. Soc. B 1973-1979.
171. Williams, D. B., S. A. Varia, V. J. Stella, and I. H. Pitman. 1983. Evaluation of the prodrug potential of the sulfate esters of acetaminophen and 3-hydroxymethyl-phenytoin. Int. J. Pharm. 14:113-120.
172. Zalipsky, S., C. Gilon, and A. Zilkha. 1983. Attachment of drugs to polyethylene glycols. Eur. Polym. J. 19:1177-1183.
173. Zhao, Z., D. G. I. Kingston, and A. R. Crosswell. 1991. Modified taxols. 6. Preparation of water soluble prodrugs of taxol. J. Nat. Prod. 54:1607-1611.
174. Zlojkowska, Z., H. J. Krasuka, and J. Pachecka. 1982. Enzymatic hydrolysis of amino acid derivatives of benzocaine. Xenobiotica 12:359-364.
175. Zou, M. J., G. Cheng, H. Okamoto, X. H. Hao, F. An, F. D. Cui, and K. Danjo. 2005. Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vitro evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates. World J. Gastroenterol. 11:7457-7460.